Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

140.41 +2.35 (+1.70%)
Streaming Delayed Price Updated: 11:03 AM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗
Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout. 
Via Chartmill
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results. 
Via Benzinga
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the Affordable Growth Profile ↗
Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and a reasonable valuation, fitting an affordable growth investing strategy. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Neurocrine Biosciences (NBIX) is a strong value stock with a debt-free balance sheet, high profitability, and solid growth, trading at a discount to its industry peers. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Q3 2025 Earnings Top Estimates, Driving Stock Momentum ↗
Neurocrine Biosciences (NBIX) smashed Q3 2025 earnings estimates, with a 26% EPS beat and strong revenue growth driven by its flagship product INGREZZA®. 
Via Chartmill
News headline image
Neurocrine Bio Surges After Crushing Third-Quarter Expectations ↗
Shares of Neurocrine Biosciences raced ahead late Tuesday on better-than-expected third-quarter sales and earnings. 
Via Investor's Business Daily
News headline image
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100... 
Via Benzinga
Topics Economy Stocks
News headline image
Examining the Future: Neurocrine Biosciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
What 13 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity ↗
Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗
Discover Neurocrine Biosciences (NBIX), a neuroscience leader with strong growth, high profitability, and a positive technical breakout setup. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million. 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology ↗
Neurocrine Biosciences (NBIX) offers solid growth and strong profitability at a reasonable valuation. This biotech stock fits the "affordable growth" strategy for long-term investors. 
Via Chartmill
News headline image
Where Neurocrine Biosciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screened as a Strong Growth Stock with Bullish Technical Setup ↗
Neurocrine Biosciences (NBIX) is a strong growth stock with accelerating revenue, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
News headline image
Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation ↗
Neurocrine Biosciences (NBIX) is a top GARP stock with strong growth, solid profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine (NBIX) Q2 Revenue Jumps 17% ↗
Via The Motley Fool
News headline image
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals ↗
Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and fair valuation, making it a top pick for affordable growth investors. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns ↗
Neurocrine Biosciences (NBIX) beat Q2 2025 revenue and EPS estimates but stock fell 8.6% amid investor concerns over guidance. INGREZZA sales grew 17% YoY. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential ↗
Neurocrine Biosciences (NBIX) shows strong growth potential with solid fundamentals, high profitability, and a bullish technical breakout pattern in the biotech sector. 
Via Chartmill
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.